HeraMED Ltd (ASX: HMD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
HeraMED Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$44.03 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.16 billion
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
8.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
HeraMED Ltd (ASX: HMD)
Latest News
Healthcare Shares
HeraMED (ASX:HMD) share price tanks despite US healthcare deal
HMD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About HeraMED Ltd
HeraMED Ltd. engages in the development and production of pregnancy monitoring solutions for home and professional use. Its product HeraBEAT, is a medical grade, foetal heart rate monitor mainly for home use. The company was founded by David Groberman and Tal Slonim on October 5, 2011 and is headquartered in Sydney, Australia.
HMD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 14 Aug 2026 | $0.04 | $0.00 | 0.00% | 93,351 | $0.04 | $0.04 | $0.04 |
| 13 Aug 2026 | $0.04 | $0.00 | 0.00% | 153,800 | $0.04 | $0.04 | $0.04 |
| 12 Aug 2026 | $0.04 | $0.00 | 0.00% | 807,011 | $0.04 | $0.04 | $0.04 |
| 11 Aug 2026 | $0.04 | $0.00 | 0.00% | 200,002 | $0.04 | $0.04 | $0.04 |
| 10 Aug 2026 | $0.04 | $0.00 | 0.00% | 104,984 | $0.03 | $0.04 | $0.03 |
| 06 Aug 2026 | $0.03 | $0.00 | 0.00% | 1,000 | $0.03 | $0.03 | $0.03 |
| 05 Aug 2026 | $0.03 | $0.00 | 0.00% | 182,159 | $0.03 | $0.03 | $0.03 |
| 04 Aug 2026 | $0.03 | $0.00 | 0.00% | 18,853 | $0.04 | $0.04 | $0.03 |
| 03 Aug 2026 | $0.04 | $0.00 | 0.00% | 1,263,963 | $0.04 | $0.04 | $0.03 |
| 31 Jul 2026 | $0.04 | $0.00 | 0.00% | 244,679 | $0.04 | $0.04 | $0.04 |
| 30 Jul 2026 | $0.04 | $0.00 | 0.00% | 3,802 | $0.04 | $0.04 | $0.04 |
| 29 Jul 2026 | $0.04 | $0.00 | 0.00% | 1,049,981 | $0.04 | $0.04 | $0.04 |
| 28 Jul 2026 | $0.04 | $0.00 | 0.00% | 1,231,485 | $0.04 | $0.04 | $0.04 |
| 27 Jul 2026 | $0.04 | $0.00 | 0.00% | 986,983 | $0.04 | $0.04 | $0.04 |
| 23 Jul 2026 | $0.04 | $0.00 | 0.00% | 197,960 | $0.04 | $0.04 | $0.04 |
| 21 Jul 2026 | $0.04 | $0.00 | 0.00% | 156,476 | $0.04 | $0.04 | $0.04 |
| 16 Jul 2026 | $0.04 | $0.00 | 0.00% | 1,210,063 | $0.04 | $0.04 | $0.04 |
| 15 Jul 2026 | $0.04 | $0.00 | 0.00% | 522,689 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Jul 2026 | Timothy (Tim) Chapman | Expiry | 3,666,666 | $139,333 |
Options expired.
|
| 30 Jun 2026 | Anoushka Gungadin | Expiry | 5,267,720 | $194,905 |
As advised by the company. 7,898,420 Rights (As per announcement); 5,267,720 rights lapsed
|
| 09 Jun 2026 | David Hinton | Issued | 2,000,000 | $80,000 |
Issue of securities. 3,500,000 Performance Rights
|
| 09 Jun 2026 | Timothy (Tim) Chapman | Issued | 3,500,000 | $140,000 |
Issue of securities. 6,000,000 Performance Rights
|
| 09 Jun 2026 | Anoushka Gungadin | Issued | 9,500,000 | $380,000 |
Issue of securities. 22,666,140 Performance Rights
|
| 09 Jun 2026 | Sharon Howell | Issued | 4,000,000 | $160,000 |
Issue of options.
|
| 21 Apr 2026 | Sharon Howell | Issued | 3,000,000 | $150,000 |
Issue of options.
|
| 21 Apr 2026 | David Hinton | Issued | 1,500,000 | $75,000 |
Issue of securities. 1,500,000 Performance Rights
|
| 21 Apr 2026 | Timothy (Tim) Chapman | Issued | 2,500,000 | $125,000 |
Issue of securities. 2,500,000 Performance Rights
|
| 02 Apr 2026 | Sharon Howell | Buy | 1,437,500 | $57,500 |
Placement.
|
| 12 Mar 2026 | Anoushka Gungadin | Exercise | 2,633,860 | $115,889 |
Conversion of securities. 13,166,140 Performance Rights
|
| 12 Mar 2026 | Anoushka Gungadin | Buy | 2,633,860 | $115,889 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Hinton | Non-Executive Director | Aug 2018 |
Mr Hinton has a career in the information and technology sectors and was previously Chief Financial Officer and Company Secretary of Empired Limited, an IT and software services provider and prior to that Amcom Telecommunications Ltd. He is also the Independent Audit Committee member of the Australian Institute of Marine Science.
|
| Mr Timothy (Tim) Chapman | Non-Executive DirectorNon-Executive Chairman | Mar 2024 |
Mr Chapman has over 25 years' experience in financial services, having advised on a myriad of corporate transactions and capital raisings for public and private companies through IPOs, private placements, reverse takeovers as well as many mergers and acquisitions. He has focused on advising and as a board member for a number on companies which have developed technologies enabling new care models through remote care across not only maternity but cardiac and diabetic management as well as aged care.
|
| Ms Anoushka Gungadin | Chief Executive OfficerExecutive Director | May 2024 |
Ms Gungadin is an experienced CEO, Board Director, and cross-border executive, witha career spanning across four continents. She is the Australian lead for TiE Women, a global mentoring and investment platform for female entrepreneurs. She is a speaker and author on inclusive leadership and cultural intelligence. Her previous experience includes founding CEO of the Australia India Chamber of Commerce set up to drive bilateral economic relationships. She headed up finance and clients accounts for Gide, the International French law firm for 10 years in Beijing.
|
| Dr Sharon Richardson Howell | Non-Executive Director | Oct 2025 |
Dr Howell is a healthcare performance and transformation executive with 20+ years of empowering people, processes, and technology across Fortune 25 health plans, start-ups, and multi-billion-dollar health systems. As Chief Performance Officer at Centene Corporation, she led enterprise-wide clinical solutions portfolios integrating care management, population health innovation, and strategic partnerships. She operates through Huntington Hill Ventures, and serves as Board Director and Chair of Advisory Board for HeraMED, bringing deep expertise in digital health, payer-provider partnerships, community health, and value-based care delivery.
|
| Mr Cameron Jones | Chief Financial OfficerCompany Secretary | Apr 2024 |
-
|
| Ms Nova Taylor | Joint Company Secretary | Jul 2026 |
-
|
| Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
|
| Nova Taylor | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Non Correlated Capital Pty Ltd | 40,000,000 | 3.59% |
| Ratdog Pty Ltd | 34,750,000 | 3.12% |
| Melbourne Securities Corporation Ltd | 34,400,000 | 3.09% |
| Always Holdings Pty Ltd | 32,212,850 | 2.89% |
| Charlton WA Pty Ltd | 31,000,000 | 2.78% |
| Mainstone Enterprises Pty Ltd | 26,804,811 | 2.41% |
| Citicorp Nominees Pty Ltd | 23,986,425 | 2.15% |
| Loxton Resources Pty Ltd | 23,470,302 | 2.11% |
| Mr Paul Gregory Brown & Mrs Jessica Oriwia Brown | 23,000,000 | 2.07% |
| S & S Browne Assets Pty Ltd | 20,537,792 | 1.84% |
| Schammer Pty Ltd | 20,526,604 | 1.84% |
| PYAP Park Pty Ltd | 20,166,320 | 1.81% |
| ML Carr Pty Ltd | 20,000,000 | 1.80% |
| BNP Paribas Nominees Pty Ltd | 19,629,528 | 1.76% |
| Isidore 14 Pty Ltd | 19,000,000 | 1.71% |
| Chris Eastwell Pty Ltd | 16,664,999 | 1.50% |
| Ascension Growth (WA) Fund Pty Ltd | 15,500,000 | 1.39% |
| Berne No 132 Nominees Pty Ltd | 14,445,583 | 1.30% |
| Kelverley Pty Ltd | 14,000,000 | 1.26% |
| BT Lithium Pty Ltd | 13,500,000 | 1.21% |
